Skip to main content
RLMD logo

RLMD · Relmada Therapeutics, Inc. · Executive Compensation

Track RLMD — free
$2.90 +0.04 (+1.40%) Play latest call Q3 2026 earnings call transcript
Market Cap
$304.61M
Shares
106.69M
Volume · Nov 19 224.8K Avg daily vol (3M) 1.41M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Charles Ence Appointed 2025-12-15
Maged Shenouda Appointed 2025-12-15
Paul Kelly Appointed 2025-12-15
Paul Kelly Appointed 2025-01-06
Eric Schmidt
“Dr. Schmidt’s resignation is not due to any disagreement with the Company, the Company’s management or the Board on any matter relating to the Company’s operations, policies or practices.”
Resigned 2023-09-06
Sergio Traversa Appointed 2023-05-25
Charles J. Casamento Appointed 2023-05-25
Fabiana Fedeli Appointed 2023-01-17
Eric Schmidt Appointed 2022-06-01

Leadership

Key facts CIK 1553643 CUSIP 75955J402 13F (30d) 150 filings 132 filers Visit website Investor relations